



(51) International Patent Classification:

A61K 39/00 (2006.01) C12N 5/0735 (2010.01)
A61K 39/39 (2006.01) C12N 5/074 (2010.01)
A61P 37/06 (2006.01) C12N 15/90 (2006.01)

(21) International Application Number:

PCT/US2021/032229

(22) International Filing Date:

13 May 2021 (13.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/025,351 15 May 2020 (15.05.2020) US

(71) Applicant: **RXCELL INC.** [US/US]; 5 Hamilton Landing,
Suite 160C, Novato, CA 94949 (US).

(72) Inventors: **ZENG, Xianmin**; 12 Sophia Court, Novato, CA
94945 (US). **RAO, Mahendra**; 15 Wilderfield Court, Tim-
onium, MD 21093 (US).

(74) Agent: **TYRRELL, Kathleen, A.** et al.; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: **HYPOIMMUNOGENIC CELLS AND USES THEREOF IN IMMUNE RESPONSES**




FIG. 1

(57) Abstract: Hypoimmunogenic cell lines useful in enhancing, invoking and/or stimulating an immune response and methods for their use and production are provided.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*